Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gynecology | 6 | 2022 | 19 | 2.410 |
Why?
|
| Clinical Competence | 8 | 2020 | 46 | 1.730 |
Why?
|
| Humans | 44 | 2025 | 4931 | 1.280 |
Why?
|
| Female | 36 | 2025 | 2964 | 1.100 |
Why?
|
| Gynecologic Surgical Procedures | 7 | 2024 | 10 | 1.090 |
Why?
|
| Urinary Incontinence, Stress | 7 | 2023 | 7 | 1.030 |
Why?
|
| Cystoscopy | 3 | 2014 | 3 | 0.920 |
Why?
|
| Vagina | 7 | 2020 | 13 | 0.860 |
Why?
|
| Obstetrics | 3 | 2020 | 18 | 0.850 |
Why?
|
| Health Equity | 1 | 2023 | 22 | 0.790 |
Why?
|
| Pelvic Floor | 7 | 2023 | 7 | 0.790 |
Why?
|
| Urinary Incontinence | 6 | 2025 | 7 | 0.790 |
Why?
|
| Pain, Postoperative | 4 | 2020 | 19 | 0.780 |
Why?
|
| Obstetric Labor Complications | 3 | 2012 | 6 | 0.770 |
Why?
|
| Endosonography | 2 | 2013 | 2 | 0.760 |
Why?
|
| Vesicovaginal Fistula | 2 | 2012 | 2 | 0.760 |
Why?
|
| Reimbursement Mechanisms | 2 | 2021 | 3 | 0.750 |
Why?
|
| Rectovaginal Fistula | 2 | 2012 | 2 | 0.710 |
Why?
|
| Internship and Residency | 4 | 2015 | 47 | 0.690 |
Why?
|
| Pelvic Organ Prolapse | 3 | 2025 | 3 | 0.680 |
Why?
|
| Medicare | 3 | 2023 | 45 | 0.640 |
Why?
|
| Anal Canal | 3 | 2014 | 3 | 0.630 |
Why?
|
| Postoperative Complications | 4 | 2025 | 82 | 0.630 |
Why?
|
| Suburethral Slings | 3 | 2023 | 3 | 0.600 |
Why?
|
| Adult | 13 | 2020 | 1402 | 0.580 |
Why?
|
| Laparoscopy | 2 | 2014 | 15 | 0.500 |
Why?
|
| United States | 8 | 2023 | 764 | 0.500 |
Why?
|
| Urination Disorders | 4 | 2012 | 6 | 0.470 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2014 | 2 | 0.460 |
Why?
|
| Ultrasonography | 4 | 2016 | 23 | 0.460 |
Why?
|
| Drug Compounding | 1 | 2014 | 2 | 0.440 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2014 | 3 | 0.440 |
Why?
|
| Drug Industry | 1 | 2014 | 5 | 0.440 |
Why?
|
| Lacerations | 1 | 2014 | 4 | 0.440 |
Why?
|
| Estrogens | 1 | 2014 | 24 | 0.440 |
Why?
|
| Estradiol | 1 | 2014 | 47 | 0.440 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 2 | 0.430 |
Why?
|
| Image Enhancement | 1 | 2013 | 3 | 0.430 |
Why?
|
| Cysts | 1 | 2013 | 3 | 0.420 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 10 | 0.420 |
Why?
|
| Teaching | 2 | 2014 | 10 | 0.410 |
Why?
|
| Middle Aged | 10 | 2020 | 1544 | 0.400 |
Why?
|
| Urology | 1 | 2012 | 1 | 0.400 |
Why?
|
| Transplants | 1 | 2012 | 1 | 0.400 |
Why?
|
| Surgical Mesh | 1 | 2012 | 4 | 0.400 |
Why?
|
| Referral and Consultation | 1 | 2012 | 45 | 0.390 |
Why?
|
| Students, Medical | 1 | 2012 | 30 | 0.390 |
Why?
|
| Histological Techniques | 1 | 2012 | 1 | 0.390 |
Why?
|
| Educational Measurement | 3 | 2020 | 17 | 0.380 |
Why?
|
| Urinary Bladder | 2 | 2011 | 11 | 0.370 |
Why?
|
| Sutures | 2 | 2009 | 4 | 0.370 |
Why?
|
| Fetal Death | 1 | 2011 | 5 | 0.360 |
Why?
|
| Pregnancy | 6 | 2014 | 417 | 0.350 |
Why?
|
| Urinary Fistula | 1 | 2010 | 2 | 0.330 |
Why?
|
| Vaginal Fistula | 1 | 2010 | 2 | 0.330 |
Why?
|
| Urethra | 4 | 2016 | 6 | 0.330 |
Why?
|
| Radiography, Interventional | 1 | 2009 | 3 | 0.310 |
Why?
|
| Contrast Media | 1 | 2009 | 14 | 0.310 |
Why?
|
| Surgeons | 2 | 2020 | 5 | 0.310 |
Why?
|
| Hysterectomy | 3 | 2025 | 10 | 0.310 |
Why?
|
| Aged | 9 | 2023 | 1188 | 0.300 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2020 | 2 | 0.290 |
Why?
|
| Retrospective Studies | 5 | 2023 | 513 | 0.290 |
Why?
|
| Pelvic Floor Disorders | 1 | 2025 | 1 | 0.240 |
Why?
|
| Obesity | 2 | 2024 | 189 | 0.230 |
Why?
|
| Analgesia | 2 | 2014 | 16 | 0.230 |
Why?
|
| Pain Management | 2 | 2014 | 21 | 0.220 |
Why?
|
| Urethral Diseases | 1 | 2003 | 1 | 0.220 |
Why?
|
| Diverticulum | 1 | 2003 | 2 | 0.220 |
Why?
|
| Task Performance and Analysis | 2 | 2014 | 4 | 0.210 |
Why?
|
| Uterine Myomectomy | 1 | 2023 | 1 | 0.210 |
Why?
|
| Women's Health | 1 | 2003 | 19 | 0.210 |
Why?
|
| Body Mass Index | 1 | 2024 | 127 | 0.200 |
Why?
|
| Leiomyoma | 1 | 2023 | 30 | 0.190 |
Why?
|
| Models, Economic | 1 | 2021 | 2 | 0.180 |
Why?
|
| Simulation Training | 1 | 2020 | 3 | 0.180 |
Why?
|
| Vulva | 1 | 2020 | 1 | 0.170 |
Why?
|
| Ketorolac | 1 | 2020 | 1 | 0.170 |
Why?
|
| Ibuprofen | 1 | 2020 | 3 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 22 | 0.170 |
Why?
|
| Urologic Surgical Procedures | 2 | 2012 | 2 | 0.150 |
Why?
|
| Fecal Incontinence | 3 | 2025 | 4 | 0.150 |
Why?
|
| Uterine Prolapse | 2 | 2012 | 5 | 0.150 |
Why?
|
| Physician Incentive Plans | 1 | 2017 | 1 | 0.140 |
Why?
|
| Practice Management | 1 | 2017 | 1 | 0.140 |
Why?
|
| Health Care Reform | 1 | 2017 | 4 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 34 | 0.140 |
Why?
|
| Oklahoma | 2 | 2015 | 3 | 0.130 |
Why?
|
| Risk Factors | 2 | 2012 | 593 | 0.130 |
Why?
|
| Suture Techniques | 2 | 2014 | 3 | 0.120 |
Why?
|
| Patient Simulation | 1 | 2015 | 2 | 0.120 |
Why?
|
| Documentation | 1 | 2015 | 6 | 0.120 |
Why?
|
| Informed Consent | 1 | 2015 | 6 | 0.120 |
Why?
|
| General Surgery | 1 | 2015 | 7 | 0.120 |
Why?
|
| Rectal Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2014 | 162 | 0.120 |
Why?
|
| Male | 3 | 2014 | 2620 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2014 | 3 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2014 | 6 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2014 | 5 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2012 | 179 | 0.120 |
Why?
|
| Uterine Diseases | 1 | 2014 | 1 | 0.110 |
Why?
|
| Professional Practice | 1 | 2014 | 2 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 5 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 58 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 407 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 8 | 0.110 |
Why?
|
| Perineum | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 53 | 0.110 |
Why?
|
| Community Health Services | 1 | 2014 | 25 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 26 | 0.110 |
Why?
|
| Polypropylenes | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2012 | 3 | 0.100 |
Why?
|
| Models, Educational | 1 | 2012 | 4 | 0.100 |
Why?
|
| Reoperation | 1 | 2012 | 16 | 0.100 |
Why?
|
| Developing Countries | 1 | 2012 | 27 | 0.100 |
Why?
|
| Pliability | 1 | 2012 | 1 | 0.100 |
Why?
|
| Parity | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cadaver | 1 | 2012 | 9 | 0.100 |
Why?
|
| Rectum | 1 | 2012 | 7 | 0.100 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 19 | 0.100 |
Why?
|
| Pain | 1 | 2012 | 30 | 0.100 |
Why?
|
| Pain Measurement | 3 | 2020 | 45 | 0.090 |
Why?
|
| Curriculum | 1 | 2012 | 44 | 0.090 |
Why?
|
| Vaginal Discharge | 1 | 2011 | 1 | 0.090 |
Why?
|
| Endometritis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cystitis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Catheters | 1 | 2011 | 6 | 0.090 |
Why?
|
| Labor, Obstetric | 1 | 2011 | 14 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 358 | 0.090 |
Why?
|
| Young Adult | 1 | 2012 | 382 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 45 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 26 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 402 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2010 | 18 | 0.080 |
Why?
|
| Fascia Lata | 1 | 2009 | 1 | 0.080 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 1 | 0.080 |
Why?
|
| Dyspareunia | 1 | 2009 | 2 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2009 | 5 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 6 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 64 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 12 | 0.080 |
Why?
|
| Adolescent | 1 | 2011 | 569 | 0.080 |
Why?
|
| Recurrence | 1 | 2009 | 25 | 0.080 |
Why?
|
| Urinary Retention | 1 | 2009 | 2 | 0.080 |
Why?
|
| Algorithms | 1 | 2009 | 69 | 0.070 |
Why?
|
| Prevalence | 2 | 2005 | 184 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 229 | 0.060 |
Why?
|
| Communication | 2 | 2016 | 23 | 0.060 |
Why?
|
| Bacteriuria | 1 | 2005 | 1 | 0.060 |
Why?
|
| Midwifery | 1 | 2005 | 1 | 0.060 |
Why?
|
| Natural Childbirth | 1 | 2005 | 1 | 0.060 |
Why?
|
| Genital Diseases, Female | 1 | 2005 | 3 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Reagent Strips | 1 | 2005 | 4 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2005 | 9 | 0.060 |
Why?
|
| Labor Stage, Second | 1 | 2005 | 5 | 0.060 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2025 | 1 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2005 | 14 | 0.060 |
Why?
|
| Actinomyces | 1 | 2005 | 1 | 0.060 |
Why?
|
| Actinomycosis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2005 | 1 | 0.060 |
Why?
|
| Vaginal Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 18 | 0.060 |
Why?
|
| Pelvis | 1 | 2003 | 5 | 0.050 |
Why?
|
| Lifting | 1 | 2003 | 1 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 41 | 0.050 |
Why?
|
| Menopause | 1 | 2003 | 4 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 33 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 35 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 24 | 0.050 |
Why?
|
| Comorbidity | 1 | 2003 | 123 | 0.050 |
Why?
|
| Syringes | 1 | 2002 | 4 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 9 | 0.050 |
Why?
|
| Collagen | 1 | 2002 | 23 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 139 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2000 | 3 | 0.040 |
Why?
|
| HIV | 1 | 2000 | 5 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 10 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2000 | 23 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2000 | 22 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 2020 | 2 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2020 | 3 | 0.040 |
Why?
|
| Bandages | 1 | 2020 | 3 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2020 | 5 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2020 | 8 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 83 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 7 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 49 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 22 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 84 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 76 | 0.040 |
Why?
|
| Incidence | 2 | 2012 | 141 | 0.040 |
Why?
|
| Aptitude | 1 | 2016 | 1 | 0.030 |
Why?
|
| Judgment | 1 | 2016 | 1 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 7 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 11 | 0.030 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2016 | 1 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 5 | 0.030 |
Why?
|
| Herniorrhaphy | 1 | 2015 | 5 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 4 | 0.030 |
Why?
|
| Psychometrics | 1 | 2014 | 10 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 5 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 4 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2014 | 27 | 0.030 |
Why?
|
| Patient Participation | 1 | 2014 | 23 | 0.030 |
Why?
|
| Analgesics | 1 | 2014 | 10 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 16 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 58 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 69 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 49 | 0.030 |
Why?
|
| Time Factors | 1 | 2012 | 245 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Urodynamics | 1 | 2005 | 3 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 10 | 0.020 |
Why?
|
| Nitrites | 1 | 2005 | 6 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 6 | 0.010 |
Why?
|
| Hematuria | 1 | 2005 | 3 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 45 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 66 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 93 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 17 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 22 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 55 | 0.010 |
Why?
|
| Bioprosthesis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Equipment Reuse | 1 | 2002 | 2 | 0.010 |
Why?
|
| Cost Savings | 1 | 2002 | 12 | 0.010 |
Why?
|
| Defecation | 1 | 2001 | 2 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 15 | 0.010 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2001 | 3 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 2000 | 2 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 6 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2000 | 11 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2000 | 8 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 58 | 0.010 |
Why?
|
| Cytokines | 1 | 2000 | 60 | 0.010 |
Why?
|